共 132 条
Estrogen and Progesterone Receptor Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Guideline Update
被引:257
作者:
Allison, Kimberly H.
[1
]
Hammond, M. Elizabeth H.
[2
]
Dowsett, Mitchell
[3
]
McKernin, Shannon E.
[4
]
Carey, Lisa A.
[5
]
Fitzgibbons, Patrick L.
[6
]
Hayes, Daniel F.
[7
]
Lakhani, Sunil R.
[8
,9
]
Chavez-MacGregor, Mariana
[10
]
Perlmutter, Jane
[11
]
Perou, Charles M.
[5
]
Regan, Meredith M.
[12
]
Rimm, David L.
[13
]
Symmans, W. Fraser
[10
]
Torlakovic, Emina E.
[14
,15
]
Varella, Leticia
[16
]
Viale, Giuseppe
[17
,18
]
Weisberg, Tracey F.
[19
]
McShane, Lisa M.
[20
]
Wolff, Antonio C.
[21
]
机构:
[1] Stanford Univ, Sch Med, Stanford, CA USA
[2] Intermt Healthcare, Salt Lake City, UT USA
[3] Royal Marsden Hosp, London, England
[4] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA
[5] Univ N Carolina, Chapel Hill, NC 27515 USA
[6] St Jude Med Ctr, Fullerton, CA USA
[7] Univ Michigan, Ann Arbor, MI 48109 USA
[8] Univ Queensland, Brisbane, Qld, Australia
[9] Pathol Queensland, Brisbane, Qld, Australia
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[11] Gemini Grp, Ann Arbor, MI USA
[12] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
[13] Yale Canc Ctr, New Haven, CT USA
[14] Saskatchewan Hlth Author, Saskatoon, SK, Canada
[15] Univ Saskatchewan, Saskatoon, SK, Canada
[16] Weill Cornell Med, New York, NY USA
[17] European Inst Oncol, Ist Ricovero & Cura Carattere Sci, IEO, Milan, Italy
[18] Univ Milan, Milan, Italy
[19] Maine Ctr Canc Med, Scarborough, ME USA
[20] NCI, Rockville, MD USA
[21] Johns Hopkins Univ, Baltimore, MD USA
关键词:
CARCINOMA IN-SITU;
ADJUVANT SYSTEMIC THERAPY;
POLYMERASE-CHAIN-REACTION;
PARAFFIN-EMBEDDED TISSUE;
MESSENGER-RNA;
HER2;
STATUS;
IMMUNOHISTOCHEMICAL SLIDES;
PROGNOSTIC-SIGNIFICANCE;
BIOMARKER ASSESSMENT;
HORMONE-RECEPTORS;
D O I:
10.5858/arpa.2019-0904-SA
中图分类号:
R446 [实验室诊断];
R-33 [实验医学、医学实验];
学科分类号:
1001 ;
摘要:
Purpose.-To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer guideline. Methods.-A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by a systematic review of the medical literature. Recommendations.-The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose. Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive. However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive. Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment. A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive. Additional strategies recommended to promote optimal performance, interpretation, and reporting of cases with an initial low to no ER staining result include establishing a laboratory-specific standard operating procedure describing additional steps used by the laboratory to confirm/adjudicate results. The status of controls should be reported for cases with 0% to 10% staining. Similar principles apply to PgR testing, which is used primarily for prognostic purposes in the setting of an ER-positive cancer. Testing of ductal carcinoma in situ (DCIS) for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered optional. Additional information can be found at www.asco.org/breast-cancer-guidelines.
引用
收藏
页码:545 / 563
页数:19
相关论文